At 18.2x earnings and 15.8x forward earnings, the market is pricing ADP as a moderate-growth compounder rather than a premium defensive franchise, yet the 1.5 Altman Z-Score signals balance sheet stress that contradicts its perceived stability. A PEG of 1.7 implies growth is not cheap relative to price, particularly when EPS next year is estimated at $10.44 versus current EPS of 11.9, suggesting near-term earnings compression. The valuation is not distressed, but it is hardly a bargain given the weak Z-score and mixed forward outlook; this looks fairly priced to slightly overvalued unless operational strength can decisively offset financial risk signals.